Clinical benefit combination of therapies. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy1

Cell Line, Tumor

Diseases44

Breast Neoplasms Neoplasm Metastasis Disease Progression Neoplasms Lung Neoplasms Recurrence Melanoma Myocardial Infarction Carcinoma, Non-Small-Cell Lung Pancreatic Neoplasms Neoplasm Recurrence, Local Gastrointestinal Stromal Tumors Adenocarcinoma Heart Failure Hemorrhage Bone Neoplasms Carcinoma, Renal Cell Prostatic Neoplasms Kidney Neoplasms Intracranial Hemorrhages Colorectal Neoplasms Chronic Disease Neoplasms, Hormone-Dependent HIV Infections Acute Disease Coronary Disease Drug-Related Side Effects and Adverse Reactions Stroke Disease Models, Animal Liver Neoplasms Arthritis, Rheumatoid Exanthema Cardiovascular Diseases Anemia Neutropenia Sarcoma Renal Artery Obstruction Pain Coronary Restenosis Brain Neoplasms Postoperative Complications Skin Neoplasms Pulmonary Disease, Chronic Obstructive Cystic Fibrosis

Chemicals and Drugs87

Antineoplastic Agents Antibodies, Monoclonal, Humanized Deoxycytidine Antibodies, Monoclonal Quinazolines Protein Kinase Inhibitors Antineoplastic Agents, Hormonal Pyrroles Platelet Aggregation Inhibitors Fluorouracil Cancer Vaccines Biomarkers, Pharmacological Receptor, erbB-2 Aromatase Inhibitors Angiogenesis Inhibitors Placebos Pyrimidines Nitriles Taxoids Triazoles Benzamides Anticoagulants Antimetabolites, Antineoplastic Tamoxifen Indoles Sirolimus Receptor, Epidermal Growth Factor Ticlopidine Piperazines Tumor Markers, Biological Hydroxymethylglutaryl-CoA Reductase Inhibitors Paclitaxel Megestrol Acetate Fibrinolytic Agents Aspirin Phenylurea Compounds Anti-Inflammatory Agents Niacinamide Benzenesulfonates Immunosuppressive Agents Vinblastine Estrogen Receptor Modulators Prenalterol Anticholesteremic Agents Anthracyclines Biological Markers Immunoglobulin Fab Fragments Doxorubicin Antirheumatic Agents Recombinant Proteins Pyridines Platelet Glycoprotein GPIIb-IIIa Complex Warfarin Methotrexate Drugs, Investigational Receptors, Estrogen Anti-HIV Agents Cisplatin Polyethylene Glycols Androstadienes Dacarbazine Anti-Inflammatory Agents, Non-Steroidal Proto-Oncogene Proteins B-raf Cyclophosphamide Organoplatinum Compounds Maytansine Thalidomide Antineoplastic Agents, Alkylating Immunologic Factors Enoxaparin Sulfasalazine Thiophenes Galantamine Antihypertensive Agents Vaccines, Subunit Antibiotics, Antineoplastic Antigens, Neoplasm Antineoplastic Agents, Phytogenic Adrenal Cortex Hormones Pyrazoles Piperidines Dioxoles Simvastatin Granulocyte Colony-Stimulating Factor Hypoglycemic Agents TOR Serine-Threonine Kinases Tubulin Modulators

Analytical, Diagnostic and Therapeutic Techniques and Equipment94

Treatment Outcome Clinical Trials as Topic Double-Blind Method Randomized Controlled Trials as Topic Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Follow-Up Studies Survival Analysis Retrospective Studies Prospective Studies Drug Therapy, Combination Kaplan-Meier Estimate Administration, Oral Survival Rate Risk Assessment Infusions, Intravenous Immunotherapy Treatment Failure Drug Approval Prognosis Patient Selection Combined Modality Therapy Clinical Trials, Phase II as Topic Neoplasm Staging Risk Factors Endpoint Determination Molecular Targeted Therapy Placebos Clinical Trials, Phase III as Topic Clinical Trials, Phase I as Topic Chemotherapy, Adjuvant Pilot Projects Therapeutic Occlusion Counterpulsation Retreatment Models, Economic Severity of Illness Index Maximum Tolerated Dose Cohort Studies Decision Support Techniques Angioplasty, Balloon, Coronary Stents Research Design Proportional Hazards Models Immunotherapy, Active Single-Blind Method Cross-Over Studies Salvage Therapy Feasibility Studies Drug Monitoring Markov Chains Predictive Value of Tests Individualized Medicine Drug Delivery Systems Palliative Care Drug Therapy Multicenter Studies as Topic Questionnaires Genetic Therapy Administration, Inhalation Disease Models, Animal Administration, Sublingual Length of Stay Injections, Subcutaneous Multivariate Analysis Myocardial Revascularization Sensitivity and Specificity Tomography, X-Ray Computed CD4 Lymphocyte Count Risk Analysis of Variance Statistics, Nonparametric Reproducibility of Results Thrombolytic Therapy Quality-Adjusted Life Years Incidence Chi-Square Distribution Confidence Intervals Models, Biological Karnofsky Performance Status Cell- and Tissue-Based Therapy Exercise Therapy Pain Measurement Immunomodulation Neoadjuvant Therapy Life Expectancy Erythrocyte Transfusion Immunohistochemistry Cardiac Pacing, Artificial Injections, Intravenous Radiotherapy, Intensity-Modulated Remission Induction Clinical Protocols

Psychiatry and Psychology2

Patient Compliance Pain

Phenomena and Processes14

Time Factors Drug Resistance, Neoplasm Dose-Response Relationship, Drug Maximum Tolerated Dose Postmenopause Markov Chains Mutation Sensitivity and Specificity CD4 Lymphocyte Count Risk Signal Transduction Pain Chi-Square Distribution Immunomodulation

Disciplines and Occupations5

Evidence-Based Medicine Research Design Individualized Medicine Outcome Assessment (Health Care)Immunohistochemistry

Anthropology, Education, Sociology and Social Phenomena4

Quality of Life Drug Approval United States Food and Drug Administration Forecasting

Technology, Industry, Agriculture2

Dietary Supplements Polyethylene Glycols

Humanities1

Quality of Life

Information Science7

Survival Rate Decision Support Techniques Questionnaires Quality-Adjusted Life Years Incidence Life Expectancy Radiotherapy, Intensity-Modulated

Health Care60

Treatment Outcome Clinical Trials as Topic Double-Blind Method Randomized Controlled Trials as Topic Disease-Free Survival Cost-Benefit Analysis Insurance Benefits Follow-Up Studies Survival Analysis Retrospective Studies Prospective Studies Kaplan-Meier Estimate Survival Rate Risk Assessment Treatment Failure Patient Selection Clinical Trials, Phase II as Topic Risk Factors Clinical Trials, Phase III as Topic Clinical Trials, Phase I as Topic United States Food and Drug Administration Pilot Projects Health Care Costs Health Benefit Plans, Employee Models, Economic Severity of Illness Index Cohort Studies Drug Costs Proportional Hazards Models Single-Blind Method Cross-Over Studies Safety Feasibility Studies Practice Guidelines as Topic Markov Chains Predictive Value of Tests Age Factors Patient Compliance Costs and Cost Analysis Palliative Care Multicenter Studies as Topic Questionnaires Outcome Assessment (Health Care)Length of Stay Multivariate Analysis Sensitivity and Specificity Risk Technology Assessment, Biomedical Analysis of Variance Statistics, Nonparametric Reproducibility of Results Quality-Adjusted Life Years Incidence Chi-Square Distribution Confidence Intervals Benchmarking Karnofsky Performance Status Patient Satisfaction Life Expectancy Clinical Protocols

Geographicals2

United States Great Britain

Anatomy Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Humanities Information Science Health Care Geographicals

Treatment Outcome Clinical Trials as Topic Antineoplastic Agents Double-Blind Method Randomized Controlled Trials as Topic Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Time Factors Disease-Free Survival Cost-Benefit Analysis Insurance Benefits Breast Neoplasms Follow-Up Studies Antibodies, Monoclonal, Humanized Neoplasm Metastasis Survival Analysis Deoxycytidine Antibodies, Monoclonal Retrospective Studies Prospective Studies Quinazolines Disease Progression Drug Therapy, Combination Neoplasms Kaplan-Meier Estimate Administration, Oral Protein Kinase Inhibitors Survival Rate Drug Resistance, Neoplasm Risk Assessment Antineoplastic Agents, Hormonal Dose-Response Relationship, Drug Quality of Life Pyrroles Infusions, Intravenous Lung Neoplasms Platelet Aggregation Inhibitors Immunotherapy Fluorouracil Cancer Vaccines Treatment Failure Drug Approval Biomarkers, Pharmacological United States Recurrence Prognosis Patient Selection Combined Modality Therapy Receptor, erbB-2 Aromatase Inhibitors Clinical Trials, Phase II as Topic Neoplasm Staging Melanoma Risk Factors Endpoint Determination Molecular Targeted Therapy Angiogenesis Inhibitors Placebos Clinical Trials, Phase III as Topic Clinical Trials, Phase I as Topic Chemotherapy, Adjuvant Myocardial Infarction United States Food and Drug Administration Pilot Projects Pyrimidines Evidence-Based Medicine Nitriles Carcinoma, Non-Small-Cell Lung Taxoids Triazoles Benzamides Anticoagulants Antimetabolites, Antineoplastic Therapeutic Occlusion Pancreatic Neoplasms Tamoxifen Counterpulsation Retreatment Health Care Costs Indoles Health Benefit Plans, Employee Models, Economic Neoplasm Recurrence, Local Sirolimus Severity of Illness Index Maximum Tolerated Dose Receptor, Epidermal Growth Factor Ticlopidine Piperazines Tumor Markers, Biological Cohort Studies Hydroxymethylglutaryl-CoA Reductase Inhibitors Gastrointestinal Stromal Tumors Decision Support Techniques Adenocarcinoma Angioplasty, Balloon, Coronary Heart Failure Paclitaxel Drug Costs Stents

No FAQ available that match "clinical benefit combination of therapies"